Novel therapeutics for brain tumors: current practice and future prospects

Area of Science:

• Neuro-oncology
• Drug Delivery
• Immunotherapy

Background:

• Malignant gliomas are aggressive primary brain tumors with limited treatment options, offering a median survival of only 20 months.
• Developing effective therapeutics for brain tumors is challenging due to the unique obstacles of the central nervous system.
• Current research focuses on improving therapeutic options to enhance patient survival.

Purpose of the Study:

• To review the obstacles in developing and delivering therapeutics into the central nervous system for neuro-oncology.
• To explore advancements in local drug delivery, including convection-enhanced delivery and high-frequency ultrasound.
• To discuss drug delivery systems, combination therapies, and immunotherapy in the context of the brain's microenvironment.

Main Methods:

• Review of current literature on neuro-oncology therapeutics.
• Analysis of successes and challenges in local drug delivery methods.
• Exploration of convection-enhanced delivery and high-frequency ultrasound for central nervous system drug delivery.
• Discussion of preclinical and clinical trials for combination therapies and immunotherapy.

Main Results:

• Convection-enhanced delivery and high-frequency ultrasound show potential for safe and effective drug delivery into the central nervous system.
• Various drug delivery systems and combination therapies are under investigation.
• Immunotherapy presents opportunities but requires consideration of the brain's unique microenvironment.

Conclusions:

• Despite incremental advances, novel therapeutics offer expanding opportunities in neuro-oncology.
• Overcoming the central nervous system's unique challenges is key to future breakthroughs in brain cancer treatment.
• Continued research into advanced drug delivery and immunotherapy is crucial for improving outcomes for malignant glioma patients.